TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04918563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
Study: NCT01016028

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.

Intervention type: BEHAVIORAL
Intervention: Sensory Tests
Description: Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.
Study: NCT03204539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wilate
Description: Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.

Intervention type: DRUG
Group type: OTHER
Intervention: Wilate
Description: Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
Study: NCT04520464

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cervical samples for identification of HR-HPV DNA via real-time PCTR.
Description: Identification of HR-HPV DNA via real-time PCTR.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cervical samples for identification of HR-HPV DNA via real-time PCTR.
Description: Identification of HR-HPV DNA via real-time PCTR.
Study: NCT03195491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous infusion administered over 30 minutes at 240 mg
Study: NCT02683967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: patients received a Delphi acupuncture at least 3 times during their fertility treatment cycle.
Study: NCT05186662

Intervention type: OTHER
Intervention: patient education
Description: patients in experimental group were asked to join a WeChat group, which was governed by experienced gastroenterologists. Relevant knowledge of H. pylori eradication was released in the group chat irregularly. Patients in WeChat group were allowed to ask questions at any time during the whole treatment process, soon afterwards, suggestions were given.

Intervention type: OTHER
Intervention: patient education
Description: Patients in the control group received verbal education and a specifically designed printout with detailed instructions.
Study: NCT02478190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tight control: goal glucose 350 mg/dL or lower
Description: Goal glucose at discharge will be 350 mg/dL or less.
Study: NCT04918563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholine
Description: Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
Study: NCT01124565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT001
Description: RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas
Study: NCT00563147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib (AV-951) plus temsirolimus
Description: ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
Study: NCT02530645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OnTrack

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing
Study: NCT02478190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loose control: goal glucose 600 mg/dL or lower
Description: Goal glucose at discharge will be 600 mg/dL or less.
Study: NCT03454373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive for linkage to care
Description: Participants who were found to have been lost to care will receive standard of care plus a one-time re-start incentive of 22,500 TZS to return to care
Study: NCT00059202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses
Study: NCT01734265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)
Study: NCT01743508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Misoprostol treatment by midwife
Description: Misoprostol treatment by midwife

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol treatment by midwife
Description: Misoprostol treatment by midwife
Study: NCT00535054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Again
Description: Liposome Eye Spray
Study: NCT03422211

Intervention type: OTHER
Intervention: Questionnaire
Description: Will ask patients questions in regards to how many narcotics they have taken and what their pain level has been.
Study: NCT00282048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (axitinib)
Description: AG-013736 5 mg twice daily \[bid\] continuous dosing in 28 day cycles.
Study: NCT01367457

Intervention type: OTHER
Intervention: Temsirolimus (Non-Interventional Study)
Description: There is not any intervention in this study.
Study: NCT02623231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
Study: NCT02349308

Intervention type: DEVICE
Intervention: CentrosFLO Long Term Hemodialysis Catheter
Study: NCT00760799

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discectomy with anular repair
Description: Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discectomy with anular repair
Description: Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
Study: NCT00858572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090 (ganetespib)
Description: Chemotherapy agent
Study: NCT03584581

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive polyphenols
Description: The amount of polyphenols to be supplied is within the ranges of absolute biosecurity food described by different authors and used in different studies.
Study: NCT00905840

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Titanium Zircon implant
Description: The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Grade IV implant
Description: The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing.
Study: NCT00059202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Urso
Study: NCT03787030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E Acetate ointment
Description: Application of 1 ml of ointment to the distal anal canal, every 12 hours for an 8-week period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl trinitrate ointment
Description: Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
Study: NCT04188106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Pill
Description: FDA approved starter kit of varenicline (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) followed by FDA-approved dose of varenicline (1 mg twice daily) for the remaining 11 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine Pill
Description: For the first week, participants will receive 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night for the remaining 12 weeks.
Study: NCT01643005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relationship Strengthening HIV Prevention Intervention
Description: The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Program Intervention
Description: Nurturing Parenting curriculum delivered in a group format.
Study: NCT01698476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)
Description: Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study: NCT03314870

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic signature
Description: To identify molecular signatures of EMT / immune status by using the random forest algorithm. The best signature will be measured by RT-qPCR and/or CATS-RNASeq technics.

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic signature
Description: To identify molecular signatures of EMT / immune status by using the random forest algorithm. The best signature will be measured by RT-qPCR and/or CATS-RNASeq technics.
Study: NCT03026348

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F Vaccine with Aluminum Phosphate Adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F Vaccine with Aluminum Phosphate Adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F Vaccine with Aluminum Phosphate Adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F Vaccine with Aluminum Phosphate Adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F Vaccine
Study: NCT03584581

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo
Study: NCT04269083

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BIRC3
Description: BIRC3-expression directed preoperative chemoradiotherapy in patients with resectable adenocarcinoma of the esophagus and EGJ

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BIRC3
Description: BIRC3-expression directed preoperative chemoradiotherapy in patients with resectable adenocarcinoma of the esophagus and EGJ
Study: NCT00548548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
Study: NCT01122056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise training
Description: Two 2-hours long interactive training to perform safe and efficient aerobic exercise for patients with multiple sclerosis
Study: NCT03851172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Ophthalmic
Description: Preoperative administration of Ketorolac 0.5% eye drops
Study: NCT00548548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
Study: NCT03851172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac Ophthalmic
Description: Preoperative administration of Nepafenac 1 mg eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclopentolate Ophthalmic
Description: Preoperative administration of Cyclopentolate eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclopentolate Ophthalmic
Description: Preoperative administration of Cyclopentolate eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclopentolate Ophthalmic
Description: Preoperative administration of Cyclopentolate eye drops
Study: NCT01836276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
Study: NCT03452475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arterolane-piperaquine
Description: Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arterolane-piperaquine+mefloquine
Description: Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg) Mefloquine tablets (250 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine tablets (20 mg/120 mg)
Study: NCT05266573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: The exercise program is led by an individual who has a background in exercise physiology and is trained by the Physical Therapist. The task oriented exercise program consists of 45 to 60 minutes of group exercise sessions with the following components: warm-up period (dual task activity and walking progressively), stretching/strengthening/balance (gradual progression of activities and repetitions for 30 minutes), and obstacle course (6 to 15 minutes of obstacle course and challenged walking).
Study: NCT00331552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given orally
Study: NCT00548548

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fluorouracil
Description: For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
Study: NCT01356381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Dosage 50mg b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 50mg bid
Study: NCT01823068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Patients will begin on once daily vandetanib at 300 mg with one cycle of 4 weeks.
Study: NCT00000479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Participants will receive 100 mg of aspirin every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Participants will receive 100 mg of aspirin every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Participants will receive 600 IU of vitamin E every other day.
Study: NCT00331552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study: NCT00000479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Participants will receive 600 IU of vitamin E every other day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo.
Study: NCT02815722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
Study: NCT00000479

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo.
Study: NCT04122599

Intervention type: DRUG
Group type: OTHER
Intervention: Melatonin
Description: Melatonin for prevent post stroke delirium
Study: NCT03514082

Intervention type: DEVICE
Intervention: Rigid Thermoplastic Spinal Brace
Description: Custom made rigid thermoplastic brace with 23 hours daily wearing time.
Study: NCT02970695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: magneto-auriculotherapy (MAT)
Description: Subjects will then receive MAT. The magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm.The experimental object will be applied to the seven selected acupoints as detected by an acupoint detector. Only one ear will receive treatment at a time, and the pellets will remain in situ for two days before the next change.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magneto-auriculotherapy (MAT)
Description: Subjects will then receive MAT. The magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm.The experimental object will be applied to the seven selected acupoints as detected by an acupoint detector. Only one ear will receive treatment at a time, and the pellets will remain in situ for two days before the next change.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser auriculotherapy (LAT)
Description: A laser device (Pointer Pulse™)15 will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm,2 and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. 16, 17 This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the selected acupoints. Laser protective goggles will be provided to the subjects and the researcher for eyes protection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser auriculotherapy (LAT)
Description: A laser device (Pointer Pulse™)15 will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm,2 and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. 16, 17 This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the selected acupoints. Laser protective goggles will be provided to the subjects and the researcher for eyes protection
Study: NCT00511043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787
Description: PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
Study: NCT03082001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12% Sucrose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24% Sucrose